Variable | Progression-free survival | Overall survival | ||||
---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||
P value | HR (95 % CI) | P value | P value | HR (95 % CI) | P value | |
Gender (female vs. male) | 0.025 | 2.61 (1.13–6.02) | 0.025 | 0.010 | ||
Age (>60 vs. ≤60 years) | 0.660 | 0.887 | ||||
ECOG score (≥2 vs. 0–1) | 0.124 | 0.015 | ||||
Stage (II vs. I) | 0.001 | 0.003 | ||||
B symptoms (yes vs. no) | 0.251 | 0.264 | ||||
LDH (elevated vs. normal) | 0.020 | 2.26 (1.01–5.07) | 0.048 | 0.001 | ||
IPI (2 vs. 0–1) | 0.006 | 0.001 | 4.29 (1.48–12.41) | 0.007 | ||
NKPI (2–3 vs. 0–1) | 0.095 | 0.058 | ||||
Chemotherapy (GELOX vs. CHOP-L) | 0.661 | 0.800 | ||||
Treatment response (non-CR vs. CR) | 0.001 | 0.001 | ||||
Histological PD-L1 (≥38 vs. <38 %) | <0.001 | 6.76 (2.91–15.69) | <0.001 | <0.001 | 7.34 (2.36–22.86) | 0.001 |